Teva Pharmaceutical Industries Ltd. $TEVA Shares Sold by Gamco Investors INC. ET AL

Gamco Investors INC. ET AL lowered its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 24.2% in the first quarter, Holdings Channel.com reports. The firm owned 66,100 shares of the company’s stock after selling 21,100 shares during the period. Gamco Investors INC. ET AL’s holdings in Teva Pharmaceutical Industries were worth $1,991,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in TEVA. Legal & General Group Plc increased its stake in shares of Teva Pharmaceutical Industries by 6.8% during the 4th quarter. Legal & General Group Plc now owns 3,608,387 shares of the company’s stock valued at $112,618,000 after acquiring an additional 228,189 shares during the last quarter. Norges Bank acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth approximately $1,098,060,000. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 8.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 1,082,578 shares of the company’s stock worth $33,506,000 after acquiring an additional 80,106 shares during the last quarter. TD Asset Management Inc grew its holdings in Teva Pharmaceutical Industries by 47.1% in the fourth quarter. TD Asset Management Inc now owns 369,023 shares of the company’s stock valued at $11,517,000 after purchasing an additional 118,075 shares during the period. Finally, Y Intercept Hong Kong Ltd purchased a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $9,126,000. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Trading Up 2.3%

Shares of TEVA stock opened at $31.81 on Wednesday. The company has a quick ratio of 0.78, a current ratio of 1.01 and a debt-to-equity ratio of 1.70. Teva Pharmaceutical Industries Ltd. has a fifty-two week low of $14.99 and a fifty-two week high of $37.35. The firm’s 50 day moving average price is $33.19 and its two-hundred day moving average price is $32.68. The stock has a market cap of $36.57 billion, a price-to-earnings ratio of 23.92, a price-to-earnings-growth ratio of 3.28 and a beta of 0.86.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings data on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. The company had revenue of $3.98 billion during the quarter. On average, analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 1.99 EPS for the current year.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, insider Mark Sabag sold 144,180 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $34.99, for a total value of $5,044,858.20. Following the completion of the sale, the insider directly owned 80,760 shares in the company, valued at approximately $2,825,792.40. This represents a 64.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Christine Fox sold 21,258 shares of the firm’s stock in a transaction dated Thursday, April 30th. The shares were sold at an average price of $35.31, for a total value of $750,619.98. Following the completion of the transaction, the executive vice president directly owned 63,647 shares in the company, valued at $2,247,375.57. This trade represents a 25.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 465,931 shares of company stock worth $16,332,989. Corporate insiders own 0.54% of the company’s stock.

Wall Street Analyst Weigh In

TEVA has been the subject of several research analyst reports. UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, April 30th. Truist Financial upped their price objective on Teva Pharmaceutical Industries from $42.00 to $45.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Barclays increased their target price on Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Piper Sandler lifted their target price on Teva Pharmaceutical Industries from $42.00 to $44.00 and gave the company an “overweight” rating in a report on Tuesday. Finally, Bank of America boosted their price target on Teva Pharmaceutical Industries from $38.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, April 9th. Nine research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.